CAR T Cell Locomotion in Solid Tumor Microenvironment | JoVE Visualize

Area of Science:

Immunotherapy
Oncology
Cellular Biology

Background:

Chimeric antigen receptor (CAR) T cell therapy has shown success in blood cancers but faces significant hurdles in treating solid tumors.
The tumor microenvironment (TME) presents suppressive barriers that impede CAR T cell function, trafficking, and survival, hindering treatment efficacy.
Current preclinical models, including in vivo animal studies and in vitro assays, have limitations in fully recapitulating the complex TME and predicting clinical outcomes.

Purpose of the Study:

To review the critical role of the tumor microenvironment (TME) in CAR T cell therapy for solid tumors.
To discuss the limitations of current preclinical models in accurately representing the TME and predicting CAR T cell therapy efficacy.
To highlight the importance of understanding these limitations for improving the development and clinical translation of CAR T cell therapies.

Main Methods:

Literature review focusing on the impact of the TME on CAR T cell therapy.
Analysis of the advantages and disadvantages of various preclinical models (in vivo and in vitro) for studying CAR T cell therapy in the context of the TME.
Discussion of the immunosuppressive mechanisms within the TME that affect CAR T cell function.

Main Results:

The TME creates an immunosuppressive environment that impairs CAR T cell trafficking, function, and persistence.
In vivo animal models offer complexity but have limitations in human biological relevance and resource intensity.
In vitro models provide mechanistic insights at the cellular level but often lack the complexity and spatial dimensions of the in vivo TME.

Conclusions:

Overcoming TME-imposed barriers is crucial for advancing CAR T cell therapy in solid tumors.
A comprehensive understanding of the strengths and weaknesses of preclinical models is essential for reliable prediction of clinical success.
Improved preclinical models that better mimic the in vivo TME are needed to optimize CAR T cell therapy development.